Why Quest Diagnostics Stock Is Getting Attention
Without a single headline event driving sentiment, Quest Diagnostics (DGX) is drawing interest as investors weigh its recent share performance alongside current profitability, revenue mix, and overall value score.
The stock’s moves over the past week and month, combined with its longer term total returns and current valuation metrics, are prompting closer attention from investors looking at large US healthcare service providers.
See our latest analysis for Quest Diagnostics.
At a share price of $191.51, Quest Diagnostics has seen a softer patch recently, with a 30-day share price return showing a 4.51% decline. However, its 1-year total shareholder return of 18.89% and 5-year total shareholder return of 62.31% indicate stronger longer term momentum building from earlier levels.
If you are comparing Quest with other healthcare names using diagnostic and data themed ideas, it can be useful to scan for opportunities in 31 healthcare AI stocks
With Quest Diagnostics trading at $191.51 alongside a value score of 5 and an indicated 36.41% intrinsic discount, the key question is whether you are looking at a genuine mispricing or a stock that already reflects future growth.
Most Popular Narrative: 12.4% Undervalued
Quest Diagnostics' most followed narrative pegs fair value at $218.50 per share, compared with the latest close of $191.51, framing the stock as undervalued on that view.
The accelerating shift toward preventive healthcare and wellness, visible in the expansion of functional medicine and consumer initiated testing, is fueling sustained demand for recurring lab services. This trend underpins expectations for stable, long term top line growth and improved revenue durability.
Curious what kind of revenue runway and margin profile this assumes? The narrative leans on steady volume gains, richer test mix, and a premium earnings multiple to justify that fair value.
Result: Fair Value of $218.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on reimbursement remaining supportive, and on wage and technology costs not eroding margins faster than Quest can offset through productivity gains.
Find out about the key risks to this Quest Diagnostics narrative.
Next Steps
With that mix of optimism and concern in mind, it is worth moving quickly to review the underlying data yourself and pressure test the balance of risks and rewards, starting with the 4 key rewards and 1 important warning sign.
Looking for more investment ideas?
If you stop with just one stock, you might miss other opportunities that fit your style, so put a few more quality names on your radar today.
- Target dependable cash generators by scanning companies with resilient finances using the solid balance sheet and fundamentals stocks screener (41 results).
- Hunt for potential bargains by focusing on companies that combine quality fundamentals with appealing pricing through the 58 high quality undervalued stocks.
- Spot lesser known prospects before the crowd by reviewing the screener containing 23 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com